Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope

Hepatology

Volumn 34, Issue 6, 2001, Pages 1206-1217

  Brinster, Carine ^a   Muguet, Stéphanie ^a   Lone, Yu Chun ^b   Boucreux, Delphine ^a   Renard, Nathalie ^a   Fournillier, Anne ^a   Lemonnier, François ^b   Inchauspé, Geneviève ^a  

^a BIOMÉRIEUX   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PLASMID DNA; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HEPATITIS C; HEPATITIS C VIRUS; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; VACCINATION; VIRUS HEPATITIS; VIRUS INFECTION;

EID: 0035192083     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.29304     Document Type: Article

References (68)

1. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
2. Transmissible agent in non-A, non-B hepatitis
3. Hepatitis C virus infection in post-transfusion hepatitis
4. The scientific challenge of hepatitis C virus
5. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma
6. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection
7. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals
8. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules
9. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif
10. Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers
11. Liver-derived CTL in hepatitis C virus infection: Breadth and specificity of responses in a cohort of persons with chronic infection
12. Analysis of a successful immune response in persons infected with hepatitis C virus
13. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained
14. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
15. Identification of HLA-A3 and -B7 restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C
16. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
17. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
18. Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection
19. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte responses in patients with chronic hepatitis C virus infection
20. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus
21. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
22. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
23. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections
24. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C
25. Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development
26. Peripheral-blood mononuclear cell responses to recombinant hepatitis C virus antigens in patients with chronic hepatitis C
27. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection
28. T-lymphocyte response to hepatitis C virus in different clinical courses of infection
29. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia
30. Association of multispecific CD4+ response to hepatitis C and severity of recurrence after liver transplantation
31. Expression and identification of hepatitis C virus polyprotein cleavage products
32. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection
33. Analysis of a successful immune response against hepatitis C virus
34. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
35. Targeting human papillomavirus type 16 E7 to the endosomal/lyosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
36. Alphavirus expression vectors and their use as recombinant vaccines - A minireview
37. Enhancing immune responses using suicidal DNA vaccines
38. Comparative analysis of humoral immune responses to HIV type I envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest Virus RNA, or Recombinant Semliki Forest Virus particles
39. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic h-2Db beta2m double knockout mice
40. Genomic structure of the human prototype strain H of hepatitis C virus: Comparison with American and Japanese isolates
41. In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes
42. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode
43. Limiting dilution assays for the determination of immuno-competent cell frequencies I. Data analysis
44. Internal processing of hepatitis C virus NS3 protein
45. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region
46. Gene vaccination: Plasmid DNA is more than just a blueprint
47. H-2 class I knockout, HLA-A2.1 transgenic mice: A versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies
48. Immunogenicity of a human Immunodeficiency Virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8+ cytotoxic T-cell epitopes
49. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization
50. DNA vaccines for hepatitis C virus
51. Gene-gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumors in the liver and lungs
52. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
53. Phagocytic processing of bacterial antigens for class 1 MHC presentation to T cells
54. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines
55. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
56. Dendritic cells acquire antigen from apoptotic cells and induce class-I-restricted CTLs
57. The Semliki Forest Virus vector induces p53-independent apoptosis
58. Cancer therapy using a self-replicating RNA vaccine
59. Semliki Forest virus vector carrying the bovine viral diarrhea virus NS3 (p80) cDNA induced immune responses in mice and expressed BVDV protein in mammalian cells
60. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine
61. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki Forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens
62. Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7
63. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection
64. Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers INF-gamma release in absence of detectable cytopathicity
65. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines
66. MHC class I/peptide stability: Implications for immunodominance, in vitro proliferation and diversity of responding CTL
67. Immudominance of major histocompatibility complex class I-restricted influenza virus epitopes can be influenced by the T-cell receptor repertoire
68. The composition of a primary T cell response is largely determined by the timing of recruitment of individual T cell clones